Akero Therapeutics (AKRO) Competitors

Akero Therapeutics (NASDAQ:AKRO) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Which has stronger valuation & earnings, AKRO or GMAB?

Genmab A/S has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akero Therapeutics	N/A	N/A	-$252.06M	-$2.00	-23.52
Genmab A/S	$3.12B	4.99	$1.14B	$1.99	12.22

Is AKRO or GMAB more profitable?

Genmab A/S has a net margin of 37.53% compared to Akero Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 21.03% beat Akero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akero Therapeutics	N/A	-15.84%	-14.59%
Genmab A/S	37.53%	21.03%	16.98%

Does the media favor AKRO or GMAB?

In the previous week, Akero Therapeutics had 2 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Akero Therapeutics and 6 mentions for Genmab A/S. Akero Therapeutics' average media sentiment score of 1.66 beat Genmab A/S's score of 0.69 indicating that Akero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akero Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals hold more shares of AKRO or GMAB?

7.1% of Genmab A/S shares are owned by institutional investors. 7.1% of Akero Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more risk & volatility, AKRO or GMAB?

Akero Therapeutics has a beta of -0.28, suggesting that its stock price is 128% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Do analysts rate AKRO or GMAB?

Akero Therapeutics presently has a consensus target price of $81.57, suggesting a potential upside of 73.45%. Genmab A/S has a consensus target price of $37.60, suggesting a potential upside of 54.67%. Given Akero Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Akero Therapeutics is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Summary

Genmab A/S beats Akero Therapeutics on 10 of the 16 factors compared between the two stocks.